Program
ganaplacide
A development code. Also written as “KLU156”.
In Novartis’s pipeline, Non-artemisinin plasmodium falciparum inhibitor
. Its studies are mostly in Malaria, Falciparum, led by Novartis.
Furthest: phase 3, since Apr 24, 20234 company-led studies, 2 open or runningNext primary completion: Feb 4, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 42 open or running | phase 3since Apr 24, 2023 | Feb 17, 2023 | Feb 4, 2027phase 2 · NCT07811908 |
- Named in Novartis’s own pipeline as
KLU156 (Ganaplacide + lumefantrine)
, phase 4, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 17, 2023First study: phase 2 study in MalariaFirst studyNCT05750628 · 327 planned · Burkina Faso, Côte d’Ivoire, Gabon and more
- Apr 24, 2023Phase 3 study in MalariaNCT05842954 · 1,720 enrolled · Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo and more
- Nov 14, 2025Phase 2 study in Malaria, FalciparumNCT07235033 · 60 enrolled · Côte d’Ivoire, Gabon, Kenya
- Sep 4, 2026Phase 2 study in Malaria, FalciparumNCT07811908 · 120 planned · Burkina Faso, Côte d’Ivoire, Gabon and more
Ahead
- Feb 4, 2027Primary completion: phase 2 study in Malaria, FalciparumNCT07811908
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Non-artemisinin plasmodium falciparum inhibitor”the company's pipeline, read by Claude · source
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07811908Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more | 2 | Recruiting | Feb 4, 2027 | 120 |
| NCT07235033Malaria, Falciparum · Côte d’Ivoire, Gabon, Kenya | 2 | Completed | Mar 5, 2025 | 60 |
| NCT05842954Malaria · Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo and more | 3 | Completed | Jun 27, 2025 | 1,720 |
| NCT05750628Malaria · Burkina Faso, Côte d’Ivoire, Gabon and more | 2 | Recruiting | Jun 9, 2026 | 327 |
How it is read
Names in the registry
- “KLU156”, 4 entries
Codes read as this program: KLU156.
Conditions, from the studies’ own filings
- Malaria, Falciparum, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.